Advertisement

Topics

FDA approves enasidenib for relapsed or refractory acute myeloid leukaemia

11:57 EDT 1 Aug 2017 | ecancermedicalscience

The U.S. Food and Drug Administration today approved enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic,...

Original Article: FDA approves enasidenib for relapsed or refractory acute myeloid leukaemia

NEXT ARTICLE

More From BioPortfolio on "FDA approves enasidenib for relapsed or refractory acute myeloid leukaemia"

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...